This profile was last updated on //
Is this you? Claim your profile.
Envision Pharma Ltd
Southport Crossing 3530 Post Road
We are a medical and scientific communications company providing strategically driven scientific and technology solutions to the pharmaceutical and biotechnology industries.
Our innovative approach provides the right mix of scientific communication serv
Find other employees at this company (410)
(12 Total References)
Thomas Gesell, BS PharmD, Business Lead Medical Affairs, Envision Technology Solutions
Tom joined Envision Technology Solutions (ETS) in 2011 to lead the creation of a new medical information solution, support ETS products, and assist customers…
extensive knowledge and experience of industry-based medical information and publications to find new solutions to improve the communication of medical evidence.
is recognized as a leader in medical information and publications where he
works actively to establish policies, implement best practices, and drive industry standards.
He is active in several international organizations where he has served as a trustee of International Society of Medical Publication Professionals (ISMPP) Board of Directors, section chair DIA Medical Communications, steering committee member for the Medical Publishing Insights and Perspectives (MPIP) initiative, and member of the USP Expert Committee for Information Development and Dissemination.
Sharon Leighton Consultancy: tag
Drivers, challenges, organisational models and critical success factors making it all possible are described, based on the experiences of the 3 speakers, Dan Kates, Gilead; Tom Gesell, Novartis and Sharon Leighton.
Tom Gesell, ...
Tom Gesell, UBC-Envision Group
Top Row L-R: Rosie Lynch, Juli Clark, Rob Matheis, Mina Patel, Tom Gesell
Novartis Pharmaceuticals Corporation
Top Row L-R: Beth Young, Stan Heimberger, Susan Siska, Tom Gesell, Rosie Lynch Bottom Row L-R: Kim Goldin, Julia Ralston, Al Weigel, Rob Matheis
News & Blog | Sharon Leighton Consultancy Ltd - Part 5
Chaired by Leena Jindia, Tibotec Therapeutics, I was privileged to speak on the topic, along with Dan Kates, Senior Director, Global Communications, Gilead and Tom Gesell, Global Head, Medical Communications, Novartis.